Wendy Dicicco

With more than 30 years of experience in life sciences, Wendy has a strong record of success in financial, operational and corporate development. Wendy has led many companies through various stages of development and commercialization. Over the last seven years she has served as a life science advisor, often in an interim executive capacity, to several emerging growth companies as they approached and successfully accomplished IPO, a transformative acquisition or merger or first-time commercialization.

Most recently, she has served as the interim Chief Financial Officer (CFO) for Akari Therapeutics (NASDAQ: AKTX) and for Renovacor (NYSE: RCOR) and FerGene, all companies advancing targeted therapeutics through the clinical pipeline to commercialization. Previously, she was Chief Operating and Financial Officer of Centinel Spine, a global commercial spinal implant developer and manufacturer. Prior to Centinel, she held several public and private company CFO roles including: Camber Spine, Nuron Biotech, Quench USA, Globus Medical and Kensey Nash Corporation. She started her career in accounting at Deloitte & Touche, LLP.

Wendy currently serves on the board of directors of EyePoint Pharmaceuticals (NASDAQ:EYPT) and Imvax, Inc. and has previously served on multiple public and private life science company boards over the last 20 years. Wendy received a B.S. in accounting from Philadelphia College of Textiles and Science and is a licensed CPA. She is also an appointed Board Leadership Fellow of the National Association of Corporate Directors (NACD).